Insider Buying Activity Heats Up at URGN
Wildman Daniel George recently acquired 8,000 shares of URGN, adding to insider buying momentum.
Key Points
- On June 22, 2026, Wildman Daniel George acquired 8,000 shares of URGN, highlighting ongoing insider interest.
- URGN shares traded near $35.80 on Wednesday, with the company's stock seeing active institutional involvement.
- Analysts like HC Wainwright & Co. and Oppenheimer maintain a 'buy' rating on URGN, with targets up to $45.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wildman Daniel George recently purchased 8,000 shares of URGN on June 22, 2026. This move is part of a broader trend of insider buying at the company. Shares of URGN were trading around $35.80 on Wednesday, reflecting a period of active insider and institutional interest.
Insider Buying and Selling at UroGen Pharma Ltd.
The recent activity at URGN saw several insiders buying shares. On June 22, 2026, James Robinson Jr. bought 18,000 shares, Leana Wen acquired 10,000 shares, Arie Belldegrun purchased 20,000 shares, and Cynthia Butitta added 10,000 shares to her holdings. These transactions were not made under a pre-planned trading scheme, suggesting a direct vote of confidence in the company's prospects.
Other Institutional Activity in URGN
Several institutional investors have also been active in URGN. BlackRock, Inc. increased its holdings by 244,558 shares, reaching 2,845,567 shares valued at about $51.16 million, marking a 9.4% increase. Toronto Dominion Bank opened a new position with 2,616,714 shares worth $47.05 million. Meanwhile, Morgan Stanley slightly reduced its position by 2,863 shares, holding 2,560,038 shares valued at approximately $46.03 million. Kynam Capital Management, LP also initiated a new stake, securing 2,247,393 shares worth about $40.41 million.
Analysts Set New Price Targets
Analysts remain bullish on URGN. On May 11, 2026, HC Wainwright & Co. maintained its 'buy' rating with a price target of $45. Similarly, Oppenheimer reaffirmed its 'buy' rating on May 7, 2026, with a target price of $40. These targets reflect analysts' confidence in the company's growth prospects.
Bottom Line
The recent insider buying activity at URGN, alongside institutional interest, suggests a strong belief in the company's future. While insider trades can offer insights into confidence levels, they are not a guarantee of future performance. Investors often pay attention to these moves as part of their broader analysis. As always, these filings are historical and may not reflect the current positions.
Get UroGen Pharma Ltd. alerts
New 13F filings, insider trades, and analyst moves on $URGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.